Trial Profile

A Cancer Research UK Phase I/II trial to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of UCB4594 alone and in combination with anti-cancer treatments in participants with advanced malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UCB-4594 (Primary)
Indications Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Adverse reactions; First in man

05 Apr 2024 Status changed from not yet recruiting to recruiting.
07 Feb 2024 Planned initiation date changed from 16 Feb 2024 to 13 Mar 2024.
24 Jan 2024 Recruitment completion is expected on 1 Nov 2028, according to ISRCTN: Current Controlled Trials.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com